Navigation Links
Chimerix Announces Late-Breaking Poster Presentation at Kidney Week 2011 Annual Meeting
Date:11/11/2011

DURHAM, N.C., Nov. 11, 2011 /PRNewswire/ -- Chimerix, Inc., a biotechnology company developing orally-available antiviral therapeutics, today announced a late-breaking poster presentation at the American Society of Nephrology's (ASN) Kidney Week 2011 Annual Meeting being held November 8-13, 2011 in Philadelphia, PA.  

V. Ram Peddi, MD, Transplant Nephrologist and Director of Kidney Transplant Research at California Pacific Medical Center, will present data from Chimerix's Phase 1/2 trial evaluating CMX001 in transplant patients with BK virus (BKV) infection.  The poster presentation, entitled "CMX001 Was Well-Tolerated and Without Nephrotoxicity in Renal Transplant and Hematopoietic Stem Cell Transplant Recipients with BK Virus Infection in a Prospective, Randomized, Double-Blind Study," is part of the "Late-Breaking Clinical Trials Poster" session and begins at 10:00 am on Saturday, November 12 at the Philadelphia Convention Center.

"In the Phase 1/2 trial, CMX001 was generally safe and well tolerated when administered to renal transplant (RT) and hematopoietic stem cell transplant (HSCT) recipients," stated Wendy Painter, MD, MPH, Chief Medical Officer of Chimerix, Inc.  "Importantly, no signs of nephrotoxicity were seen following five weekly oral doses of 40 mg and the pharmacokinetics of CMX001 and cidofovir were similar between kidney transplant and bone marrow transplant recipients."  These findings are consistent with results from other CMX001 clinical trials and based on Chimerix's experience with subjects treated under emergency INDs.

CMX001 is being tested in ongoing placebo-controlled clinical trials and in open-label treatment protocols for the prophylaxis, pre-emption and treatment of double-stranded DNA (dsDNA) viruses, including herpesviruses and adenoviruses, and as a potential biodefense countermeasure in the event of a smallpox release.  Data from an ongoing, placebo-controlled Phase 2 clinical trial
'/>"/>

SOURCE Chimerix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Chimerix to Present at Stifel Nicolaus 2011 Healthcare Conference
2. Chimerix Commences Phase 2 Clinical Study of CMX001 for Prevention of Adenovirus Disease in Pediatric and Adult Hematopoietic Stem Cell Transplant Patients
3. Chimerix and BARDA Reach Agreement Ending GAO Review of Smallpox Antiviral Contract
4. Chimerix to Present at Two Upcoming Investor Conferences
5. Chimerix Awarded BARDA Contract for Advanced Development of Broad Spectrum Antiviral CMX001 as Medical Countermeasure Against Smallpox
6. Chimerix Completes $45 Million Financing to Fund Further Development of Novel Antiviral Therapeutics CMX001 and CMX157
7. Chimerix Presents Update on CMX001 Development to the World Health Organization Advisory Committee on Variola Virus Research
8. Chimerixs PIM Conjugate Technology Reduces Risk of Nephrotoxicity for CMX001 and CMX157
9. Chimerix Appoints Two New Vice Presidents to Clinical Management Team
10. Chimerix to Present at Upcoming Investor Conferences
11. Chimerix Initiates Phase 1 Study of CMX157
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/31/2015)... March 31, 2015 This June 13th, ... the top U.S and International Medical Schools will come ... research on the application of stem cell therapy in ... is organized and funded by the Ocular Research ... has been convening intimate meetings of top experts in ...
(Date:3/31/2015)... Today, Cryos International, the world’s largest international ... facilities and inventory from New York City to Orlando, ... relocation is a reflection of their increasing growth and ... completed during the first weekend of spring, March 21 ... April 6. The new facility in the Central Florida ...
(Date:3/31/2015)... OH (PRWEB) March 31, 2015 Diasome ... its licensor, SDG, Inc., that a United States patent ... liver-targeted insulin therapy. , Entitled “Lipid Construct ... covers composition of matter claims related to the use ... system for enabling injected insulin to more effectively reach ...
(Date:3/31/2015)... Campbell, California (PRWEB) March 31, 2015 ... management consulting firm with operations in California, Oregon, ... formal launch of its Merger and Acquisition (M&A) ... , Peter Adams, VP Client Services and M&A ... repeatedly shown that the vast majority of M&A ...
Breaking Biology Technology:Sight Restoration Through Stem Cell Therapy - Subject of June Symposium of Experts 2Cryos International Completes Groundbreaking Sperm Migration to Orlando, Florida 2Diasome Pharmaceuticals, Inc. Announces Notice of Allowance from US PTO for Liver Targeting System for Insulin 2Lighthouse Information Systems, Inc., Announces Addition of M&A Integration Services 2
... Pfizer Cox-2 inhibitor Bextra from the marketplace clearly jolted both Pfizer ... Vioxx dilemma months ago and its stock has declined from $38 ... February. It has recently moved up to the $27 level. , ... the last 12 months. , ,Though Pfizer still leads the industry ...
... Milwaukee Badger Meter Inc. (AMEX:BMI) reported ... the quarter ended March 31, a profit jump of 42 ... metering products for water systems, including a wireless display that ... for the same quarter last year were $2.4 million, on ...
... (NYSE:SXT) reported $12.8 million in profits on $251.9 million ... earnings per share were 27 cents. Sensient is a global ... was down $3 million since the same quarter last year. ... , ,Results for the first quarter include a one-time expense ...
Cached Biology Technology:Why are new drugs failing? 2Why are new drugs failing? 3Why are new drugs failing? 4Why are new drugs failing? 5Why are new drugs failing? 6
(Date:3/30/2015)... and Markets ( http://www.researchandmarkets.com/research/lc9bnl/global_gesture ) has announced ... in Automotive Sector 2014-2018" report to their offering. ... market in Automotive Sector to grow at a CAGR ... recognition is the ability of a device to identify ... recognition technology can be 2D-based or 3D-based. It uses ...
(Date:3/26/2015)... , March 26, 2015 ... family, social, recreation and athletic club, today announced it ... to allow freedom of movement for members and staff, ... "Following a comprehensive process, we selected FST,s IMID Access ... and convenience for our members and staff, in addition ...
(Date:3/24/2015)... and Markets ( http://www.researchandmarkets.com/research/hdgz7h/global_iris ) has announced ... 2015-2019" report to their offering. The ... at a CAGR of 23.5 percent over the period ... and the growth prospects of the Global Iris Recognition ... size, the report considers the revenue generated from sales ...
Breaking Biology News(10 mins):Global Gesture Recognition Market in Automotive Sector Report 2015 - Growing Number of Partnerships 2Granite Club First Private Club in North America to Implement FST Biometrics Secure Access Solution, as Part of Multi-million Dollar Expansion 2Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2
... WI, May 31, 2010 A study of undergraduates ... students perceive as important change as they progress through ... and create more attractive forestry programs to reverse the ... and others from the University of Eastern Finland, as ...
... discovered a way of mimicking the stunningly bright ... tropical butterflies. The findings could have important applications ... bank notes and credit cards harder to forge. ... butterflies and other insects have long fascinated both ...
... MOSS LANDING, CA MBARI,s Division of Marine Operations, ... Administration (NOAA), sent a high-tech robotic submersible to the ... is to collect information about the oil plume from ... Although satellites and aircraft can help show the extent ...
Cached Biology News:Perceptions of forestry students change through years of study 2From butterflies' wings to bank notes -- how nature's colors could cut bank fraud 2MBARI sends underwater robot to study Deepwater Horizon spill 2
... • Enzyme concentration - 5 units/µL ,• ... higher yields ,• Leaves an 'A' overhang ... polymerase which exhibits very high activity in ... To ensure the quality of the enzyme, ...
Our original highly-purified, robust Taq Polymerase which delivers consistently high yields and minimal background...
... AmpliTaq DNA Polymerase is the ... PCR process, a testimony to its overall ... profile makes it ideal for PCR applications. ... guarantee reproducible results. ,, AmpliTaq DNA ...
... Taq DNA Polymerase is a versatile and ... all PCR applications. GCpro Taq DNA Polymerase ... in E. coli, containing the DNA polymerase ... includes a highly processive 5'-3' DNA polymerase ...
Biology Products: